Express Scripts Raises Pressure on Gilead for Drug Price

Express Scripts Holding Co., a pharmacy benefit manager that handles more than 1 billion prescriptions a year in the U.S., is ratcheting up its effort to force Gilead Sciences Inc. to cut the $84,000 price of its new hepatitis C pill Sovaldi.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.